FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2387483003> ?p ?o ?g. }

• W2387483003 endingPage "e275" @default.
• W2387483003 startingPage "e267" @default.
• W2387483003 abstract "Background Little information is available about the clinical history of patients with incidentally detected splanchnic vein thrombosis and its therapeutic management remains controversial. The aim of this study was to assess the risk factors, therapeutic strategies, and long-term outcomes of incidentally detected splanchnic vein thrombosis. Methods We analysed data from patients with incidentally detected splanchnic vein thrombosis who were enrolled in an international, multicentre, prospective cohort study of splanchnic vein thrombosis between 2008 and 2012. The study was done at 31 centres in 11 countries (Italy, South Korea, Germany, Canada, Belgium, the Netherlands, Brazil, USA, France, Israel, UK). Information about demographic characteristics, risk factors, and treatment was collected. The study outcomes during the 2-year follow-up were major bleeding (International Society on Thrombosis and Haemostasis definition plus the need for hospital admission), thrombotic events (venous or arterial thromboses), and mortality. The primary analysis period was from the diagnosis of incidentally detected splanchnic vein thrombosis until the first adjudicated clinical outcome or the end of follow-up. Findings Between May 2, 2008, and Jan 30, 2012, we enrolled 177 patients with incidentally detected splanchnic vein thrombosis (median age 57 years [IQR 49–66], 118 [67%] men, 138 [78%] patients with portal vein thrombosis). The most common underlying diseases were liver cirrhosis (82 [46%] patients) and solid cancer (62 [35%] patients). Anticoagulant treatment was prescribed to 109 (62%) patients. Median duration of anticoagulation was 6 months (IQR 5–12) for patients who received parenteral anticoagulants alone and 24 months (IQR 12–24) for patients treated with vitamin K antagonists. During a median follow-up of 2 years (IQR 1–2), the incidence of major bleeding was 3·3 events (95% CI 1·7–6·3) per 100 patient-years and the incidence of thrombotic events was 8·0 events (95% CI 5·2–12·1) per 100 patient-years. On-treatment incidence was 3·2 events (95% CI 1·2–8·4) per 100 patient-years for major bleeding and 3·9 events (95% CI 1·6–9·5) per 100 patient-years for thrombotic events. In multivariate analysis, anticoagulant treatment as a time-dependent variable reduced the incidence of thrombotic events (hazard ratio 0·85, 95% CI 0·76–0·96) without increasing the risk of major bleeding (p>0·05). In patients with clinically suspected splanchnic vein thrombosis, the incidence of major bleeding was 3·9 events (95% CI 2·6–5·7) per 100 patient-years and the incidence of thrombotic events was 7·0 events (95% CI 5·2–9·3) per 100 patient-years. Interpretation Our results show that the prognosis of incidentally detected splanchnic vein thrombosis is similar to that of clinically suspected splanchnic vein thrombosis and suggest that similar treatment strategies should be applied. Funding Pfizer Canada research grant." @default.
• W2387483003 created "2016-06-24" @default.
• W2387483003 creator A5004003194 @default.
• W2387483003 creator A5011055840 @default.
• W2387483003 creator A5012674794 @default.
• W2387483003 creator A5013053286 @default.
• W2387483003 creator A5022945946 @default.
• W2387483003 creator A5038099524 @default.
• W2387483003 creator A5049728223 @default.
• W2387483003 creator A5057224314 @default.
• W2387483003 creator A5057802451 @default.
• W2387483003 creator A5081041579 @default.
• W2387483003 creator A5083115765 @default.
• W2387483003 creator A5085695670 @default.
• W2387483003 date "2016-06-01" @default.
• W2387483003 modified "2023-10-16" @default.
• W2387483003 title "Clinical history and antithrombotic treatment of incidentally detected splanchnic vein thrombosis: a multicentre, international prospective registry" @default.
• W2387483003 cites W1506072545 @default.
• W2387483003 cites W1516162587 @default.
• W2387483003 cites W1523107736 @default.
• W2387483003 cites W1576854676 @default.
• W2387483003 cites W1861743845 @default.
• W2387483003 cites W1998788312 @default.
• W2387483003 cites W2011826456 @default.
• W2387483003 cites W2021969922 @default.
• W2387483003 cites W2031156548 @default.
• W2387483003 cites W2032537572 @default.
• W2387483003 cites W2047345200 @default.
• W2387483003 cites W2048441761 @default.
• W2387483003 cites W2059796825 @default.
• W2387483003 cites W2081117694 @default.
• W2387483003 cites W2090387429 @default.
• W2387483003 cites W2094642669 @default.
• W2387483003 cites W2110420855 @default.
• W2387483003 cites W2113501944 @default.
• W2387483003 cites W2131099415 @default.
• W2387483003 cites W2138741992 @default.
• W2387483003 cites W2146404132 @default.
• W2387483003 cites W2161090555 @default.
• W2387483003 cites W2162193963 @default.
• W2387483003 cites W2166046225 @default.
• W2387483003 cites W2989714602 @default.
• W2387483003 cites W571628560 @default.
• W2387483003 doi "https://doi.org/10.1016/s2352-3026(16)30020-5" @default.
• W2387483003 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27264036" @default.
• W2387483003 hasPublicationYear "2016" @default.
• W2387483003 type Work @default.
• W2387483003 sameAs 2387483003 @default.
• W2387483003 citedByCount "47" @default.
• W2387483003 countsByYear W23874830032016 @default.
• W2387483003 countsByYear W23874830032017 @default.
• W2387483003 countsByYear W23874830032018 @default.
• W2387483003 countsByYear W23874830032019 @default.
• W2387483003 countsByYear W23874830032020 @default.
• W2387483003 countsByYear W23874830032021 @default.
• W2387483003 countsByYear W23874830032022 @default.
• W2387483003 countsByYear W23874830032023 @default.
• W2387483003 crossrefType "journal-article" @default.
• W2387483003 hasAuthorship W2387483003A5004003194 @default.
• W2387483003 hasAuthorship W2387483003A5011055840 @default.
• W2387483003 hasAuthorship W2387483003A5012674794 @default.
• W2387483003 hasAuthorship W2387483003A5013053286 @default.
• W2387483003 hasAuthorship W2387483003A5022945946 @default.
• W2387483003 hasAuthorship W2387483003A5038099524 @default.
• W2387483003 hasAuthorship W2387483003A5049728223 @default.
• W2387483003 hasAuthorship W2387483003A5057224314 @default.
• W2387483003 hasAuthorship W2387483003A5057802451 @default.
• W2387483003 hasAuthorship W2387483003A5081041579 @default.
• W2387483003 hasAuthorship W2387483003A5083115765 @default.
• W2387483003 hasAuthorship W2387483003A5085695670 @default.
• W2387483003 hasConcept C126322002 @default.
• W2387483003 hasConcept C141071460 @default.
• W2387483003 hasConcept C188816634 @default.
• W2387483003 hasConcept C2777015399 @default.
• W2387483003 hasConcept C2778800853 @default.
• W2387483003 hasConcept C2780011451 @default.
• W2387483003 hasConcept C2780868729 @default.
• W2387483003 hasConcept C71924100 @default.
• W2387483003 hasConceptScore W2387483003C126322002 @default.
• W2387483003 hasConceptScore W2387483003C141071460 @default.
• W2387483003 hasConceptScore W2387483003C188816634 @default.
• W2387483003 hasConceptScore W2387483003C2777015399 @default.
• W2387483003 hasConceptScore W2387483003C2778800853 @default.
• W2387483003 hasConceptScore W2387483003C2780011451 @default.
• W2387483003 hasConceptScore W2387483003C2780868729 @default.
• W2387483003 hasConceptScore W2387483003C71924100 @default.
• W2387483003 hasFunder F4320333564 @default.
• W2387483003 hasIssue "6" @default.
• W2387483003 hasLocation W23874830031 @default.
• W2387483003 hasLocation W23874830032 @default.
• W2387483003 hasOpenAccess W2387483003 @default.
• W2387483003 hasPrimaryLocation W23874830031 @default.
• W2387483003 hasRelatedWork W148041586 @default.
• W2387483003 hasRelatedWork W1987488025 @default.
• W2387483003 hasRelatedWork W2030717199 @default.
• W2387483003 hasRelatedWork W2059299277 @default.
• W2387483003 hasRelatedWork W2091403084 @default.
• W2387483003 hasRelatedWork W2403061077 @default.

• next